[Mary Zawadzki]

In this open-label, phase 3 trial, patients were randomly assigned who were previously untreated HLA-A*02:01–positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. Read more here: https://www.nejm.org/doi/full/10.1056/NEJMoa2103485

• This topic was modified 4 months, 1 week ago by Mary Zawadzki.

[Author]

Posts